Type 1 Diabetes Triggers, Drivers, Modifying Factors


HealtheSolutions.com-Cause-Cure-Type 1 Diabetes Triggers, Drivers, Modifying FactorsHealth-e-Solutions comment: The researchers put forth a hypothesis for the pathogenic development of type 1 diabetes. They make distinctions between Type 1 Diabetes Triggers, Drivers, Modifying Factors, all of which they believe to be involved in type 1 diabetes development and progression, along with genetic susceptibility in some individuals. It is a hypothesis supported by the interpretation of 93 other research articles, but remains speculative until definitive causal proof can be established.

The first signs of beta-cell autoimmunity may appear very early in life. We have focused our research on defining the characteristics of the trigger(s) of beta-cell autoimmunity by observing subjects with increased HLA-conferred susceptibility to type 1 diabetes prospectively from birth, with frequent follow-up visits with an interval of 3–6 months up to the age of 2 years and thereafter with an interval of 6–12 months (26). These studies have revealed that there is an unequivocal temporal variation in the appearance of the first diabetes-associated autoantibodies reflecting the initiation of the disease process and paralleling the seasonal variation previously observed in the presentation of clinical diabetes (10,27). Most initial autoantibodies appear during the cold period in the fall and winter but rarely in the spring or in the summer. There also seems to be some variation from one year to another in the timing and height of the autoantibody peaks. When studying families with more than one child experiencing seroconversion to autoantibody positivity, we have noticed that the autoantibodies rarely appear simultaneously in seroconverting siblings (28). The first autoantibodies do emerge, however, more often than expected during the same season among such siblings but infrequently in the same year. Based on these observations,

“[W]e conclude that the trigger of beta-cell autoimmunity 1) has a seasonal pattern, being more common during the cold season; 2) shows some temporal variation from year to year; and 3) does not necessarily induce beta-cell autoimmunity at the same time in all genetically susceptible siblings within the same family.”

Based on the characteristics listed above, some exogenous factors implicated as potential triggers of beta-cell autoimmunity may be excluded. These include exogenous factors with a stable or consistently increasing exposure, such as most dietary components in early childhood. The pattern of the autoantibody appearance strongly points to the role of infectious agents with conspicuous seasonal variation as triggers of beta-cell autoimmunity. Such variations are typical for viral infections, and the pattern of laboratory-confirmed enterovirus infections in Finland fits well into the proposed role of enterovirus infections as triggers of beta-cell autoimmunity (Fig. 3B). In addition to viral infections, one should also consider other environmental variables with seasonal variation. There is definitely seasonal variation in the amount of daylight and sunshine hours, especially in Northern Europe, which has the highest incidence of type 1 diabetes in the world (29). Without oral substitution, the sunlight-dependent synthesis of vitamin D in the skin is the most important source of this immunologically active hormone. Some studies have indicated that the lack of oral vitamin D substitution in infancy increases the subsequent risk of type 1 diabetes (30,31). The following two arguments do, however, speak against the role of vitamin D deficiency as a trigger of beta-cell autoimmunity: 1) there is a general recommendation that all young children should take daily vitamin D drops in Northern Europe, and this recommendation is implemented by >95% of the parents, at least in children up to the age of 2 years; and 2) there are regions with a low type 1 diabetes incidence in Northern Europe, e.g., Russian Karelia, having an annual incidence rate of 7.8/100,000 children under the age of 15 years in the time period of 1990–1999 compared with a rate of 42 in Finland (32). It has been shown that the mean HbA1c level varies over the year in children with manifest type 1 diabetes, with the highest values in the fall and winter and with lower levels in the spring and summer (33–35). This may reflect improved insulin sensitivity in the spring and summer because of more physical exercise. Improved insulin sensitivity diminishes beta-cell stress, as the workload on the beta-cells decreases. However, it is unlikely that there should be substantial seasonal variation in physical exercise in very young children, the target group in whom the seasonal variation in the appearance of the first diabetes-associated autoantibodies has been observed.

Accordingly, we are left with viral infections as the most likely explanation for the seasonal variation in the emergence of the first signs of beta-cell autoimmunity. Taken into account the timing and profiles of the autoantibody peaks observed in the Finnish DIPP study, enterovirus infections appear to be the most probable trigger of beta-cell autoimmunity. This is supported by our previous observations of a strong temporal relationship between enterovirus infections and the appearance of the first diabetes-associated autoantibodies in two prospective series of young children with increased genetic susceptibility to type 1 diabetes (36–40).

The implicated link between enterovirus infections and beta-cell autoimmunity has been questioned, since most of the supportive data have come out of Finnish studies. Two other prospective studies (BABYDIAB in Germany and the Diabetes Autoimmunity Study in the Young [DAISY] in Denver, CO) have failed to demonstrate any association between enterovirus infections and beta-cell autoimmunity (41,42). There are, however, at least three critical issues with a decisive impact on the ability of any prospective study to provide meaningful observations in this context. The first one is the size of the study and the number of subjects who develop signs of beta-cell autoimmunity—factors clearly related to the statistical power of the study (43). All prospective studies have so far included <50 seroconverters, which confers a high risk of missing even major influences of enterovirus infections on beta-cell autoimmunity.

A second critical consideration is the study design and the sampling interval. Long sampling intervals definitely hamper the possibility to detect enterovirus infections from collected samples. In the BABYDIAB study, coxsackie virus antibodies were measured from serum samples taken at the age of 9 months, 2 years, 5 years, and 8 years, and in DAISY, the samples were obtained at the age of 9 months, 15 months, 2 years, and then annually. In contrast, the DIPP study has a more frequent sampling schedule, collecting samples with an interval of 3–6 months over the first 2 years of life and subsequently with an interval of 6–12 months.

The third crucial point is related to the type of samples collected and the methodological arsenal used for the detection of enterovirus infections, taking into account that there are more than 60 different serotypes. The DIPP study used the most extensive strategy, including detection of enterovirus mRNA with polymerase chain reaction from serum and stool samples and analysis of IgA, IgM, and IgG class enterovirus antibodies using both group- and serotype-specific assays. The impact of these differences is reflected by the substantially lower frequency of infections diagnosed, e.g., in the BABYDIAB cohort compared with the DIPP study (7 vs. 81% of the children had had an enterovirus infection by the age of 2 years). It is unlikely that such a difference could be due to a lower frequency of enterovirus infections in Germany, because enterovirus infections actually seem to be more common in the background population in Germany than in Finland (44). In addition to these prospective studies, a series of cross-sectional surveys have documented that enterovirus infections are more common in patients with newly diagnosed type 1 diabetes than in control subjects (45). For example, enterovirus RNA has been detected in the peripheral blood on average in one-third of the patients with type 1 diabetes but in <5% of the control subjects.

The frequency of enterovirus infections has decreased over the last decades in the background population in developed countries, e.g., in Finland and Sweden (44). Despite that, these countries have a high and increasing incidence of type 1 diabetes among children. This appears to be paradoxical. The paradox can, however, be explained by the so-called “polio hypothesis” introduced by Viskari et al. (46). The polioviruses comprise three serotypes among >60 enterovirus serotypes. When the frequency of acute poliovirus infections started to decrease at the beginning of the last century among the general population in countries with an increasing standard of hygiene, the incidence of paralytic polio being a complication of the acute infection began to increase. This was obviously the consequence of decreased levels of protective maternal poliovirus antibodies transferred transplacentally and through breast milk to the infant, leading to a situation where the risk increased that the infant would get his or her first poliovirus infection at the time of no maternal protection. Similarly, the decreasing frequency of enterovirus infections in the background population would increase the susceptibility of young children to the diabetogenic effect of enteroviruses. The same phenomenon may also contribute to the marked international variation in type 1 diabetes incidence, because enterovirus infections seem to be rare in countries where the rate of type 1 diabetes is high (44).

The tropism phenomenon (the characteristic of a virus to infect a particular tissue or cell type), in which the attachment of the virus to the viral receptors on the cell surface together with other interactions with cellular proteins is a central feature, is thought to explain why some variants of enteroviruses may be diabetogenic and others not (47). It has been proposed that pancreatic beta-cell tropic variants of the coxsackie B virus are present in the general population and that they are able to induce beta-cell damage in susceptible individuals (48). The biological significance of enterovirus tropism has been demonstrated by the highly specific nature of the motor-neuron damage in poliomyelitis, and it is possible that viral tropism could also explain the specificity of beta-cell damage in type 1 diabetes. In vitro studies have shown that enteroviruses infect beta-cells easily and induce functional impairment and cell death (49,50). Such a capacity seems to be shared by a wide range of serotypes, but the extent of the cellular lesions appears to be characteristic of individual virus strains. Recent studies have shown that enterovirus genome or enterovirus proteins can be detected in pancreatic islets of patients affected by type 1 diabetes or autoantibody-positive subjects (51–53). These findings suggest that enteroviruses have a tropism for islet cells in humans in contrast to the mouse models where enteroviruses infect preferentially exocrine pancreas and only certain strains can cause beta-cell damage. They also raise the possibility that patients with type 1 diabetes may have a persistent enterovirus infection in their pancreatic islets.

An Australian study reported a few years ago molecular homology between the VP7 protein of rotavirus and T-cell epitopes in the protein tyrosine phosphatase–related IA-2 molecule and in the GAD65 molecule (54). In a prospective study of infants genetically predisposed to type 1 diabetes, the appearance of diabetes-associated autoantibodies was associated with a significant rise in rotavirus antibodies, indicating that rotavirus infections may induce beta-cell autoimmunity in genetically susceptible infants (55). A Finnish prospective study showed that ∼16% of infants and young children with HLA-conferred susceptibility to type 1 diabetes experienced a rotavirus infection during the 6-month window preceding the detection of the first diabetes-associated autoantibodies, whereas 15% of the control subjects matched for sex, birth date, delivery hospital, and HLA genotype had signs of a rotavirus infection during the corresponding time period (56). That observation does not support the role of rotavirus infections as triggers of beta-cell autoimmunity.

Taken together, accumulated data support the hypothesis that a diabetogenic enterovirus infection is the likely trigger of beta-cell autoimmunity.


There is no direct evidence of an exogenous antigen driving the type 1 diabetes disease process from initial beta-cell autoimmunity to clinical disease. Accordingly, this idea is based on indirect data and parallels with celiac disease, and it has to be critically considered. In general terms, one may argue that the driving antigen must represent a relatively common exposure among the population in most developed countries, and one can also assume that there must be some variability in the exposure within and across populations. In addition, one may hypothesize that the candidate antigen must comprise original or processed structural motifs bound by HLA molecules encoded by major histocompatibility complex class II susceptibility genes and presented effectively to T-cells by antigen-presenting cells.

Celiac disease again provides interesting angles of approach to these issues. The causal link between wheat and celiac disease was only uncovered through (unplanned) intervention: the wheat-deficient World War II diet in the Netherlands and its postwar improvement identified a culprit autoimmune disease-causing agent, i.e., dietary gluten (57). Without that experience, gluten would have remained most likely unidentified as the driving dietary antigen in celiac disease. It has recently been proposed that the HLA association in celiac disease, in which HLA DR3-DQ2 is the dominant susceptibility haplotype, can be explained by a superior ability of the DQ2 molecule to bind proline-rich gluten peptides that have survived gastrointestinal digestion and have been deamidated by tissue transglutaminase (58). This brings up two thought-provoking points. First, the most important auto-antigen in celiac disease, i.e., tissue transglutaminase, seems to have a biological role in the disease process. Second, the exogenous antigen, i.e., gluten, must be processed in a critical manner (in this case deamidated) before it is bound by the predisposing HLA molecule to be presented to T-cells.

Insulin is a crucial auto-antigen in type 1 diabetes because it is the only beta-cell–specific auto-antigen in postnatal life. IAAs are the first or among the first autoantibodies to appear when the disease process leading to type 1 diabetes is initiated in young children (9,10). The frequency of IAAs is also substantially higher among young children at the diagnosis of type 1 diabetes than among older children and adults (59). Because cow’s milk formulas generally are the first and most common dietary source of foreign complex proteins to which an infant is exposed in developed countries, we asked the question whether early exposure to cow’s milk formula results in an immune response to bovine insulin present in formulas and differing from human insulin by three amino acids: two in the A chain and one in the B chain. Our study showed that the infants who were exclusively breast-fed at least up to the age of 3 months had substantially lower IgG class antibodies to bovine insulin than those who were exposed to formula before that age (60). All subjects were observed up to the age of 18 months. The follow-up demonstrated that the IgG class insulin antibodies started to slowly decrease after the age of 3 months as a sign of the development of oral tolerance in those infants who were given formula before the age of 3 months, whereas in those exclusively breast-fed at least to the age of 3 months, the antibody levels increased up to the age of 12 months, after which the antibody titers leveled off. That antibody profile was expected, since these infants were exposed to cow’s milk–based products, mostly formula, at some point during their first 12 months of life. The study cohort included a small series of subjects (n = 11) who developed early signs of beta-cell autoimmunity. These subjects showed continuously increasing levels of IgG antibodies to bovine insulin. This increase may partly be explained by the appearance of IAAs, since there is a considerable cross-reactivity between bovine and human insulin in the insulin antibody assays. However, the increase in IgG antibodies to bovine insulin remained significant, even after adjustment for the IAA titers. Our observation indicates that those young children who present with early signs of beta-cell autoimmunity appear to lack the capacity to develop oral tolerance to bovine insulin. Accordingly, the initial immune response to bovine insulin may be diverted into a response targeting human insulin in such individuals.

Are there then any data suggesting that increased exposure to cow’s milk later in childhood might confer increased risk for type 1 diabetes? Data from three population-based case-control studies on cow’s milk intake before diagnosis of type 1 diabetes are conflicting. Verge et al. (61) reported that the cow’s milk intake had been higher in pre-diabetic children than in control children in New South Wales, Australia. In our nationwide Childhood Diabetes in Finland (DiMe) study, we observed that a high consumption of cow’s milk in childhood was associated with a more frequent appearance of diabetes-associated autoantibodies and type 1 diabetes in a prospective cohort of initially unaffected siblings of children with type 1 diabetes (62,63). In contrast, a Swedish retrospective survey indicated that the frequency of milk intake had been lower among children who presented with type 1 diabetes than among unaffected children (64).

Increased circulating antibody levels to cow’s milk proteins were reported in children with type 1 diabetes for the first time in 1988, when Savilahti et al. (65) observed that such children had significantly higher levels of serum IgA antibodies to cow’s milk and β-lactoglobulin and of IgG antibodies to β-lactoglobulin than age-matched control subjects. This finding has been confirmed by later studies (2). Dahlquist et al. (66) reported from the Swedish nationwide case-control study that most cow’s milk antibody levels tended to be increased in diabetic children when compared with control subjects, the difference being significant for IgA antibodies to cow’s milk, BSA, and β-lactoglobulin. In a multiple logistic regression analysis, the authors observed that IgA antibodies to β-lactoglobulin were significantly associated with an increased risk of diabetes at young age, independent of islet cell antibody status and of early weaning to cow’s milk–based formula. These observations could be interpreted as supporting the idea that enhanced consumption of cow’s milk before the presentation of clinical type 1 diabetes is a risk factor. There are, however, also alternative explanations to the increased circulating cow’s milk antibody levels in children with newly diagnosed type 1 diabetes. The immunological reactivity to cow’s milk proteins may be enhanced in children who will progress to type 1 diabetes or their gastrointestinal permeability to cow’s milk proteins might be increased. The enhanced humoral immune response to cow’s milk proteins seem to be specific for type 1 diabetes because elevated levels have not been generally observed in other autoimmune diseases. The active immune response has been reported to be restricted to cow’s milk proteins, since patients with newly diagnosed type 1 diabetes have not been shown to have increased antibody levels to other dietary antigens, such as gliadin and ovalbumin (65,67). Bovine insulin antibodies have not been measured in children with signs of beta-cell autoimmunity beyond the age of 18 months, but increased levels of bovine insulin-binding antibodies have been detected in children with type 1 diabetes (60).

Taken together, the evidence in favor of the role of bovine insulin as a driving antigen in the disease process leading to overt type 1 diabetes is relatively fragmentary, and further research is clearly needed to confirm or exclude this hypothesis. Bovine insulin is definitely present in cow’s milk, although the structural components of immunoreactive insulin are poorly characterized in milk.

Gluten or other cereal-derived proteins have been implicated as potential driving antigens in type 1 diabetes. Two small-scale pilot intervention studies have been performed in family members testing positive for diabetes-associated autoantibodies to assess whether gluten elimination modifies the natural course of beta-cell autoimmunity. In the German trial, seven autoantibody-positive first-degree relatives were placed on a gluten-free diet for a period of 12 months followed by gluten re-exposure over the subsequent 12 months (68). The autoantibody titers did not change significantly during the gluten-free intervention period nor during the re-exposure period. A total of 17 family members testing positive for at least two diabetes-associated autoantibodies were put on a gluten-free diet for 6 months in an Italian trial (69) and then again on a normal diet for another 6 months. There were no significant changes in the autoantibody titers during the intervention period or during the subsequent 6 months. The first-phase insulin response to intravenous glucose increased in 12 of 14 subjects tested during the gluten-free period and decreased in 10 out 13 retested family members during the re-exposure period. Accordingly, this trial indicated that a gluten-free diet has no effect on the signs of beta-cell autoimmunity in first-degree relatives of affected patients, but such a diet may increase the endogenous insulin secretion in family members at increased risk of type 1 diabetes.

From a theoretical point of view, a dietary antigen would fit well into the role as the factor driving the disease process toward clinical type 1 diabetes, since the exposure to most dietary factors tends to be frequent, and still there is some variation in the exposure both within and across populations. Bovine insulin is an attractive candidate, since an immune response initially induced by bovine insulin will cross-react and may target human insulin in the beta-cell.


There is a conspicuous interindividual variation in the duration of the preclinical disease process in type 1 diabetes. Although some of this difference may be due to genetic elements (70), there is likely in addition a series of non-genetic host-related and exogenous factors having an impact on the fate and pace of the disease process.

Early exposure to complex foreign proteins in infancy may be a factor that affects the programming of the immune system in such a way that autoimmune responses are favored later in childhood. The gut-associated lymphoid tissue represents the largest immune organ in the human organism, and accumulating evidence suggests that gut-associated lymphoid tissue is involved in the diabetic disease process (71–73). A subclinical intestinal immune activation demonstrated as increased expression of adhesion molecules, HLA class II molecules, and cytokines has been observed in patients with type 1 diabetes without any signs of celiac disease (74,75). Early nutrition has indeed been implicated as a potential risk factor for later type 1 diabetes (76). Cow’s milk proteins are the first foreign proteins an infant is exposed to in more than two-thirds of all infants in developed countries. A series of retrospective studies have implied that breast-feeding protects from type 1 diabetes, but there are also reports suggesting no protective effect and even some indicating a predisposing effect of breast-feeding (2). In 1994, Gerstein (77) conducted a meta-analysis of all acceptable retrospective studies available to assess whether early feeding practices had any influence on the risk of type 1 diabetes. That meta-analysis showed that breast-feeding for a shorter period than 3 months was associated with a 1.4-fold risk for type 1 diabetes, whereas exposure to cow’s milk before the age of 4 months conferred a 1.5-fold disease risk. Prospective and cohort studies on the association between early feeding and the appearance of beta-cell autoimmunity, i.e., diabetes-associated autoantibodies, have also provided partly conflicting results. A cohort study from Colorado did not observe any effect of breast-feeding/early exposure to cow’s milk on the appearance of beta-cell autoimmunity similarly to two prospective studies: one from Germany and the other from Australia. In contrast, a Finnish birth cohort study reported that short exclusive breast-feeding and early exposure to cow’s milk predisposed young children to progressive beta-cell autoimmunity in the form of positivity for all four autoantibody specificities analyzed (3).

Two recent prospective studies have indicated that early exposure to cereals may increase the risk of seroconversion to positivity for diabetes-associated autoantibodies (78,79). The American report suggested that both early (before the age of 4 months) and late (at the age of 7 months or later) exposure to cereals were associated with an increased risk of beta-cell autoimmunity, whereas the German study implied that an increased risk was related to exposure to cereals before the age of 3 months. In addition, the American survey indicated that both gluten-containing and non–gluten-containing cereals conferred an increased risk for beta-cell autoimmunity. Neither of the studies reported any data on the amount and type of cereals the infants were exposed to at various ages. Early exposure to cereals is against generally accepted recommendations on infant nutrition in all developed countries and occurs only rarely. Accordingly, one may ask whether early exposure to cereals is a proxy of other baby care practices possibly predisposing to type 1 diabetes. Dietary gliadin may however trigger intestinal inflammation in subjects with type 1 diabetes likely because of the presence of the HLA DQ2/DQ8 genotype capable of binding gliadin-derived peptides (75). Wheat gliadin could thus affect the immune activation stage of the gut immune system in individuals at genetic risk for type 1 diabetes and modify the autoimmune process toward beta-cell destruction.

A pilot intervention study conducted mainly in Finland determining whether weaning to a highly hydrolyzed formula over the first 6–8 months of life decreases the cumulative incidence of diabetes-associated autoantibodies indicated that such a dietary intervention resulted in a decreased frequency of positivity for islet cell antibodies and at least one diabetes-associated autoantibody by the age of 6 years (80).

This is the first indication that it may be possible to manipulate spontaneous beta-cell autoimmunity in humans by avoiding early exposure to complex foreign proteins.

Based on the experiences from the pilot study, a randomized double-blinded trial proper was initiated in 2002 to answer the question whether it is possible to reduce the frequency of diabetes-associated autoantibodies and/or clinical type 1 diabetes by the age of 6 years and the cumulative incidence of type 1 diabetes by the age of 10 years by weaning to a highly hydrolyzed formula over the first 6–8 months of life. This Trial to Reduce IDDM in the Genetically at Risk (TRIGR) will recruit 2,032 infants with at least one affected family member and HLA-conferred susceptibility to type 1 diabetes by the end of 2006, and accordingly the final answer will be available at the earliest in year 2013, illustrating the need for long follow-up periods in prospective and intervention studies exploring the association between early feeding and later type 1 diabetes.

As mentioned earlier, vitamin D has been implicated as a risk factor for type 1 diabetes. The daily requirement of vitamin D cannot be met in the infant period without supplementation, particularly not in countries located far from the equator, which have decreased daylight in the wintertime. A European retrospective multicenter survey indicated that vitamin D supplementation during infancy was associated with a reduced risk of type 1 diabetes (30). A Finnish birth cohort study showed that vitamin D supplementation in the infant period was related to a decreased risk of type 1 diabetes, whereas suspicion of rickets by the age of 2 years increased the risk of later diabetes (31). These observations suggest that vitamin D supplementation in the infant period confers partial protection against type 1 diabetes.

Increased weight gain in infancy has repeatedly been reported to be a risk factor for type 1 diabetes later in childhood (3). A Finnish study showed that those children who presented with type 1 diabetes had been not only heavier but also taller in infancy (81). Increased height and weight later in childhood turned out to be definite risk factors for type 1 diabetes as well (82). Accelerated linear growth and weight gain result in an enhanced beta-cell load and increasing insulin resistance. It has been shown experimentally that active beta-cells are more prone to cytokine-induced damage than resting cells. This implies that rapid growth induces beta-cell stress. According to the accelerator hypothesis presented by Wilkin (83) a few years ago, insulin resistance is an important factor affecting the rising incidence of both type 1 and type 2 diabetes. The only differences between these two forms of diabetes are the pace of progression to overt disease and the fact that individuals who present with type 1 diabetes carry genetic susceptibility to autoimmunity.


The identification of exogenous factors triggering and driving beta-cell destruction offers potential means for intervention aimed at the prevention of type 1 diabetes. Therefore, it is important to pursue studies on the role of environmental factors in the pathogenesis of this disease.

Environmental modification is likely to offer the most powerful strategy for effective prevention of type 1 diabetes, since such an approach can target the whole population or at least that proportion of the population carrying increased genetic disease susceptibility and would therefore prevent both sporadic and familial type 1 diabetes if successful.

This consideration is crucial, since the sporadic cases comprise 83–98% of all children with newly diagnosed diabetes, according to a comparative European survey (87). The preliminary results of the second pilot study of the TRIGR (Trial to Reduce IDDM in the Genetically at Risk) project, suggesting that it is possible to manipulate the spontaneous appearance of beta-cell autoimmunity by dietary modification early in life in high-risk individuals, represent the first indication that environmental modification may affect the natural history of preclinical type 1 diabetes (80).

It is important to keep in mind that there are gene-environmental interactions operating in all phases of the disease process of type 1 diabetes, not only in the induction of beta-cell autoimmunity. The delineation of such interactions is challenging and requires both new methodological tools and study cohorts large enough for the analyses of interactions. So far, there are only a few examples of gene-environmental interactions implicated to play a role in the development of type 1 diabetes. The findings in two case-control studies suggested that there might be an interaction between increased genetic disease susceptibility, based on HLA class II alleles, and an early introduction of supplementary milk feeding during infancy on the risk of type 1 diabetes (88,89). A Finnish study indicated that the increased relative risk associated with childhood milk consumption may be higher among siblings of affected children carrying HLA class II genotypes conferring strong or moderate disease susceptibility than among those with low or decreased risk genotypes (63). HLA risk alleles for type 1 diabetes have also been linked to the appearance of autoantibodies subsequent to enterovirus infections (37) and to increased immune responsiveness to enterovirus antigens (90). Another consideration that has to be taken into account is that there may be interactions between two or more environmental factors. However, extensive study cohorts are needed to identify such interactions. A recent Finnish study implied that two environmental risk factors for type 1 diabetes, i.e., an early enterovirus infection and early exposure to cow’s milk, can, when present concomitantly, boost the immune response to bovine insulin in infants with increased HLA-defined disease predisposition (91).

The scientific challenges in the near future are to define the most likely environmental culprit(s) and booster(s) of beta-cell autoimmunity and to delineate how exogenous factors affect the natural history of type 1 diabetes.


  1. Dahlquist G: Environmental risk factors in human type 1 diabetes: an epidemiological perspective. Diabetes Metab Rev11 :37 –46,1995 Medline
  2. Åkerblom HK, Knip M: Putative environmental factors in type 1 diabetes. Diabetes Metab Rev14 :31 –67,1998 Medline
  3. Åkerblom HK, Vaarala O, Hyöty H, Ilonen J, Knip M: Environmental factors in the etiology of type 1 diabetes. Am J Med Genet115 :18 –29,2002 CrossRefMedline
  4. Ilonen J, Sjöroos M, Knip M, Veijola R, Simell O, Åkerblom HK, Paschou P, Bozas E, Havarini B, Malamitsi-Puchner A, Thymelli J, Vazeou A, Bartsocas CS: Estimation of genetic risk for type 1 diabetes. Am J Med Genet115 :30 –36,2002 CrossRefMedline
  5. Knip M: Natural course of preclinical type 1 diabetes. Horm Res57 (Suppl. 1) :6 –11,2002
  6. Knip M: Can we predict type 1 diabetes in the general population? Diabetes Care25 :623 –625,2002 FREE Full Text
  7. Bingley PJ, Bonifacio E, Williams AJK, Genovese S, Bottazzo GF, Gale EAM: Prediction of IDDM in the general populations: strategies based on combinations of autoantibody markers. Diabetes46 :1701 –1710,1995
  8. LaGasse JM, Brantley MS, Leech NJ, Rowe RE, Monks S, Palmer JP, Nepom GT, McCulloch DK, Hagopian WA: Successful prospective prediction of type 1 diabetes in schoolchildren by multiple defined autoantibodies: eight year follow-up of the Washington State Diabetes Prediction Study. Diabetes Care25 :505 –511,2002 Abstract/FREE Full Text
  9. Ziegler A-G, Hummel M, Schenker M, Bonifacio E: Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes48 :460 –468,1999 Abstract
  10. Kimpimäki T, Kupila A, Hämäläinen A-M, Kukko M, Kulmala P, Savola K, Simell T, Muona P, Ilonen J, Simell O, Knip M: The first signs of beta-cell autoimmunity appear in infancy in genetically susceptible children from the general population: the Finnish Type 1 Diabetes Prediction and Prevention Study. J Clin Endocrinol Metab86 :4782 –4788,2001 Abstract/FREE Full Text
  11. Kukko M, Kimpimäki T, Korhonen S, Kupila A, Simell S, Veijola R, Simell T, Ilonen J, Simell O, Knip M: Dynamics of diabetes-associated autoantibodies in young children with HLA-conferred risk of type 1 diabetes recruited from the general population. J Clin Endocrinol Metab90 :2712 –2717,2005 Abstract/FREE Full Text
  12. Kupila A, Muona P, Ronkainen M, Simell T, Erkkilä S, Arvilommi P, Korhonen S, Kimpimäki T, Sjöroos M, Ilonen J, Knip M, Simell O: Genetic risk determines the emergence of diabetes-associated autoantibodies in young children. Diabetes51 :646 –651,2002 Abstract/FREE Full Text
  13. Mrena S, Savola K, Kulmala P, Åkerblom HK, Knip M, the Childhood Diabetes in Finland Study Group: Natural course of preclinical type 1 diabetes in siblings of affected children. Acta Paediatr92 :1403 –1410,2003 Medline
  14. Kimpimäki T, Kulmala P, Savola K, Vähäsalo P, Reijonen H, Ilonen J, Åkerblom HK, Knip M, the Childhod Diabetes in Finland Study Group: Disease-associated autoantibodies as surrogate markers of type 1 diabetes in young children at increased genetic risk. J Clin Endocrinol Metab85 :1126 –1130,2000 Abstract/FREE Full Text
  15. Barnett AH, Eff C, Leslie RDG, Pyke DA: Diabetes in identical twins: a study of 200 pairs. Diabetologia20 :87 –93,1981 CrossRefMedline
  16. Kaprio J, Tuomilehto J, Koskenvuo M, Romanov K, Reunanen A, Eriksson J, Stengård J, Kesäniemi YA: Concordance for type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland. Diabetologia35 :1060 –1067,1992 CrossRefMedline
  17. EURODIAB ACE Study Group: Variation and trends in incidence of childhood diabetes in Europe. Lancet355 :873 –876,2000 CrossRefMedline
  18. Gale EA: The rise of childhood type 1 diabetes in the 20th century. Diabetes51 :3353 –3361,2002 Abstract/FREE Full Text
  19. Hermann R, Knip M, Veijola R, Simell O, Laine AP, Åkerblom HK, Groop PH, Forsblom C, Petterson-Fernholm K, Ilonen J, the FINDIANE Study Group: Temporal changes in the frequencies of HLA genotypes in patients with type 1 diabetes: indication of an increased environmental pressure? Diabetologia46 :420 –425,2003 Medline
  20. Gillespie KM, Bain SC, Barnett AH, Bingley PJ, Christie MR, Gill GV, Gale EA: The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet364 :1645 –1647,2004 CrossRefMedline
  21. Leslie RD, Delli Castelli M: Age-dependent influences on the origins of autoimmune diabetes: evidence and implications. Diabetes53 :3033 –3040,2004 FREE Full Text
  22. Alaedini A, Green PH: Narrative review: celiac disease: understanding a complex autoimmune disorder. Ann Intern Med142 :289 –298,2005 Abstract/FREE Full Text
  23. Mäki M, Mustalahti K, Kokkonen J, Kulmala P, Haapalahti M, Karttunen T, Ilonen J, Laurila K, Dahlbom I, Hansson T, Gut H, Höpfl P, Knip M: Prevalence of celiac disease in children in Finland. N Engl J Med348 :2517 –2524,2003 CrossRefMedline
  24. Kagnoff MF, Paterson YJ, Kumar PJ, Kasarda DD, Carbone FR, Unsworth DJ, Austin RK: Evidence for the role of human intestinal adenovirus in the pathogenesis of celiac disease. Gut28 :995 –1001,1987 Abstract/FREE Full Text
  25. Lähdeaho ML, Parkkonen P, Reunala T, Mäki M, Lehtinen M: Antibodies to the E1bprotein-derived peptides of enteric adenovirus type 40 are associated with celiac disease and dermatitis herpetiformis. Clin Immunol Immunopathol69 :300 –305,1993 Medline
  26. Kupila A, Muona P, Simell T, Arvilommi P, Savolainen H, Hämäläinen AM, Korhonen S, Kimpimäki T, Sjöroos M, Ilonen J, Knip M, Simell O: Feasibility of genetic and immunological prediction of type 1 diabetes in a population-based birth cohort. Diabetologia44 :290 –297,2001 CrossRefMedline
  27. Laron Z: Lessons from recent epidemiological studies in type 1 childhood diabetes. J Pediatr Endocrinol Metab12 (Suppl. 3) :733 –736,1999
  28. Kukko M, Toivonen A, Kupila A, Korhonen S, Keskinen P, Veijola R, Virtanen SM, Ilonen J, Simell O, Knip M: Familial clustering of beta-cell autoimmunity in initially non-diabetic children. Diabetes Metab Res Rev 2005 [Epub ahead of print]
  29. Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J, for the Diabetes Mondiale (DiaMond) Project Group: Incidence of childhood type 1 diabetes worldwide. Diabetes Care23 :1516 –1526,2000 Abstract
  30. EURODIAB Substudy 2 Study Group: Vitamin D supplement in early childhood and risk of type I (insulin-dependent) diabetes mellitus. Diabetologia42 :51 –54,1999 CrossRefMedline
  31. Hyppönen E, Läärä E, Järvelin MR, Virtanen SM: Intake of vitamin D and risk of type 1 diabetes: a birth cohort study. Lancet358 :1500 –1504,2001 CrossRefMedline
  32. Kondrashova A, Reunanen A, Romanov A, Karvonen A, Viskari H, Vesikari T, Ilonen J, Knip M, Hyöty H: A sixfold gradient in the incidence of type 1 diabetes at the eastern border of Finland: evidence for the role of environmental factors in the disease pathogenesis. Ann Med37 :67 –72,2005 CrossRefMedline
  33. Käär ML, Åkerblom HK, Huttunen NP, Knip M, Säkkinen K: Metabolic control of children and adolescents with insulin-dependent diabetes mellitus. Acta Paediatr Scand73 :102 –108,1984 Medline
  34. Hinde FR, Standen PJ, Mann NP, Johnston DI: Seasonal variation of haemoglobin A1 in children with insulin-dependent diabetes mellitus. Eur J Pediatr148 :146 –147,1989
  35. Nordfeldt S, Ludvigsson J: Seasonal variation of HbA1c in intensive treatment of children with type 1 diabetes. J Pediatr Endocrinol Metab13 :529 –535,2000 Medline
  36. Hyöty H, Hiltunen M, Knip M, Laakkonen M, Vähäsalo P, Karjalainen J, Koskela P, Roivainen M, Leinikki P, Hovi T, Åkerblom HK, the Childhood Diabetes in Finland Study Group: A prospective study of the role of Coxsackie B and other enterovirus infections in the pathogenesis of IDDM. Diabetes44 :652 –657,1995 Medline
  37. Hiltunen M, Hyöty H, Knip M, Ilonen J, Reijonen H, Vähäsalo P, Roivainen M, Leinikki P, Hovi T, Åkerblom HK, the Childhood Diabetes in Finland Study Group: ICA seroconversion in children is temporally associated with enterovirus infections. J Infect Dis175 :554 –560,1997 Abstract/FREE Full Text
  38. Lönnrot M, Salminen K, Knip M: Savola K, Kulmala P, Leinikki P, Hyypiä T, Åkerblom HK, Hyöty H, the Childhood Diabetes in Finland Study Group: Enterovirus RNA in serum is a risk factor for beta-cell autoimmunity and clinical type 1 diabetes: a prospective study. J Med Virol61 :214 –220,2000 CrossRefMedline
  39. Lönnrot M, Korpela K, Knip M, Ilonen J, Simell O, Korhonen S, Savola K, Muona P, Simell T, Koskela P, Hyöty H: Enterovirus infection as a risk factor for beta-cell autoimmunity in a prospectively observed birth cohort: The Finnish Diabetes Prediction and Prevention (DIPP) Study. Diabetes49 :1314 –1318,2000 Abstract
  40. Salminen K, Sadeharju K, Lönnrot M, Vähäsalo P, Ilonen J, Simell O, Knip M, Hyöty H: Enterovirus infections are associated with the induction of beta-cell autoimmunity in a prospective birth cohort study. J Med Virol69 :91 –98,2003 CrossRefMedline
  41. Fuchtenbusch M, Irnstetter A, Jager G, Ziegler AG: No evidence for an association of coxsackie virus infections during pregnancy and early childhood with development of islet autoantibodies in offspring of mothers or fathers with type 1 diabetes. J Autoimmun17 :333 –340,2001 CrossRefMedline
  42. Graves PM, Rotbart HA, Nix WA, Pallanch MA, Erlich HA, Norris JM, Hoffman M, Eisenbarth GS, Rewers M: Prospective study of enteroviral infections and development of beta-cell autoimmunity: Diabetes Autoimmunity Study in the Young (DAISY). Diabetes Res Clin Pract59 :51 –61,2003 CrossRefMedline
  43. Dahlquist G: Environmental factors and type 1 diabetes. Diabetes Care24 :180 –182,2001 FREE Full Text
  44. Viskari H, Ludvigsson J, Uibo R, Salur L, Marciulionyte D, Skrodediene E, Hermann R, Soltesz G, Fuechtenbusch M, Ziegler AG, Kondrashova A, Romanov A, Kaplan B, Laron Z, Koskela P, Vesikari T, Knip M, Hyöty H: Relationship between the incidence of type 1 diabetes and maternal enterovirus antibodies: time trends and geographical variation. Diabetologia48 :1280 –1287,2005 CrossRefMedline
  45. Hyöty H: Environmental causes of type 1 diabetes: viral causes. Endocrinol Metab Clin North Am33 :27 –44,2004 CrossRefMedline
  46. Viskari HR, Koskela P, Lönnrot M, Luonuansuu S, Reunanen A, Baer N, Hyöty H: Can enterovirus infections explain the increasing incidence of type 1 diabetes? Diabetes Care23 :414 –416,2000 Medline
  47. Fohlman J, Friman G: Is juvenile diabetes a viral disease? Ann Med25 :569 –574,1993 Medline
  48. Szopa TM, Ward T, Dronfield DM, Portwood ND, Taylor KW: Coxsackie B4 viruses with the potential to damage beta cells of the islets are present in clinical isolates. Diabetologia33 :325 –328,1990 CrossRefMedline
  49. Roivainen M, Rasilainen S, Ylipaasto P, Nissinen R, Ustinov J, Bouwens L, Eizirik DL, Hovi T, Otonkoski T: Mechanisms of coxsackievirus-induced damage to human pancreatic beta-cells. J Clin Endocrinol Metab85 :432 –440,2000 Abstract/FREE Full Text
  50. Roivainen M, Ylipaasto P, Savolainen C, Galama J, Hovi T, Otonkoski T: Functional impairment and killing of human beta cells by enteroviruses: the capacity is shared by a wide range of serotypes, but the extent is a characteristic of individual virus strains. Diabetologia45 :693 –702,2002 CrossRefMedline
  51. Dotta F, Santangelo C, Marselli L, Dionisi S, Scipioni A, Masini M, van Halteren A, Del Prato S, Di Mario U, Roep BO, Marchetti P: Demonstration of enterovirus infection in islets of two patients with type 1 diabetes. Diabetes Metab Res Rev18 (Suppl. 2) :S16 ,2002
  52. Gianini R, Dotta F, Di Mario U, Scipioni A, Grasetti D, Liggins C, Yu L, Eisenbarth GS: Screening of organ donors for anti-islet antibodies and characterization of pancreatic histology in an antibody-positive subject. Abstract book, Immunology of Diabetes Society Meeting, Cambridge, U.K., 28–31 March 2004, p. 40
  53. Ylipaasto P, Klingel K, Lindberg AM, Otonkoski T, Kandolf R, Hovi T, Roivainen M: Enterovirus infection in human pancreatic islet cells, islet tropism in vivo and receptor involvement in cultured islet beta cells. Diabetologia47 :225 –239,2004 CrossRefMedline
  54. Honeyman MC, Stone NL, Harrison LC: T-cell epitopes in type 1 diabetes autoantigen tyrosine phosphatase IA-2: potential for mimicry with rotavirus and other environmental agents. Mol Med4 :231 –239,1998 Medline
  55. Honeyman MC, Coulson BS, Stone NL, Gellert SA, Goldwater PN, Steele CE, Couper JJ, Tait BD, Colman PG, Harrison LC: Association between rotavirus infection and pancreatic islet autoimmunity in children at risk of developing type 1 diabetes. Diabetes49 :1319 –1324,1999
  56. Blomquist M, Juhela S, Erkkilä S, Korhonen S, Simell T, Kupila A, Vaarala O, Simell O, Knip M, Ilonen J: Rotavirus infections and development of diabetes-associated autoantibodies during the first 2 years of life. Clin Exp Immunol128 :511 –515,2002 CrossRefMedline
  57. Streng J: Over de beoordeling van de voedingstoestand in de praktijk. On the judgment of the state of nutrition in practice (in Dutch, summary in English). Maandschrift v Kindergen14 :67 –78,1946
  58. Kim CY, Quarsten H, Bergseng E, Khosla C, Sollid LM: Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc Natl Acad Sci U S A101 :4175 –4179,2004 Abstract/FREE Full Text
  59. Sabbah E, Savola K, Ebeling T, Kulmala P, Vähäsalo P, Salmela P, Knip M: Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes mellitus. Diabetes Care23 :1326 –1332,2000 Abstract/FREE Full Text
  60. Vaarala O, Knip M, Paronen J, Hämäläinen A-M, Muona P, Väätäinen M, Ilonen J, Simell O, Åkerblom HK: Cow milk formula feeding induces primary immunization to insulin in infants at genetic risk for type 1 diabetes. Diabetes48 :1389 –1394,1999 Abstract
  61. Verge CF, Howard NJ, Irwig L, Simpson JM, Mackerras D, Silink M: Environmental factors in childhood IDDM: a population-based case-control study. Diabetes Care17 :1381 –1389,1994 Abstract/FREE Full Text
  62. Virtanen SM, Hyppönen E, Läärä E, Vähäsalo P, Kulmala P, Savola K, Räsänen L, Knip M, Åkerblom HK, the Childhood Diabetes in Finland Study Group: Cow’s milk consumption, disease associated autoantibodies and type 1 diabetes mellitus: a follow-up study in siblings of diabetic children. Diabet Med15 :730 –738,1998 CrossRefMedline
  63. Virtanen SM, Läärä E, Hyppönen E, Reijonen H, Räsänen L, Aro A, Knip M, Ilonen J, Åkerblom HK, the Childhood Diabetes in Finland Study Group: Cow’s milk consumption, HLA-DQB1 genotype, and type 1 diabetes: a nested case-control study of siblings of children with diabetes. Diabetes49 :912 –917,2000 Abstract
  64. Dahlquist GG, Blom L, Persson L-Å, Sandström AIM, Wall SGI: Dietary factors and the risk of developing insulin dependent diabetes in childhood. Br Med J300 :1302 –1306,1990
  65. Savilahti E, Åkerblom HK, Tainio V-M, Koskimies S: Children with newly diagnosed insulin dependent diabetes mellitus have increased levels of cow’s milk antibodies. Diabetes Res7 :137 –140,1988 Medline
  66. Dahlquist G, Savilahti E, Landin-Olsson M: An increased level of antibodies to beta-lactoglobulin is a risk determinant for early-onset type 1 (insulin-dependent) diabetes mellitus independent of islet cell antibodies and early introduction of cow’s milk. Diabetologia35 :980 –984,1992 CrossRefMedline
  67. Saukkonen T, Savilahti E, Vaarala O, Virtala ET, Tuomilehto J, Åkerblom HK, the Childhood Diabetes in Finland Study Group: Children with newly diagnosed IDDM have increased levels of antibodies to bovine serum albumin but not to ovalbumin. Diabetes Care17 :970 –976,1994 Abstract/FREE Full Text
  68. Hummel M, Bonifacio E, Naserke HE, Ziegler AG: Elimination of dietary gluten does not reduce titers of type 1 diabetes-associated autoantibodies in high-risk subjects. Diabetes Care25 :1111 –1116,2002 Abstract/FREE Full Text
  69. Pastore MR, Bazzigaluppi E, Belloni C, Arcovio C, Bonifacio E, Bosi E: Six months of gluten-free diet do not influence autoantibody titers, but improve insulin secretion in subjects at high risk for type 1 diabetes. J Clin Endocrinol Metab88 :162 –165,2003 Abstract/FREE Full Text
  70. Mrena S, Savola K, Kulmala P, Reijonen H, Ilonen J, Åkerblom HK, Knip M, the Childhood Diabetes in Finland Study Group: Genetic modification of risk assessment based on staging of preclinical type 1 diabetes in siblings of affected children. J Clin Endocrinol Metab88 :2682 –2689,2003 Abstract/FREE Full Text
  71. Harrison LC, Honeyman MC: Cow’s milk and type 1 diabetes: the real debate is about mucosal immune function. Diabetes48 :1501 –1507,1999 Abstract
  72. Vaarala O: Gut and the induction of immune tolerance in type 1 diabetes. Diabete Metab Res Rev15 :353 –361,1999
  73. Vaarala O: The gut immune system and type 1 diabetes Ann N Y Acad Sci958 :39 –46,2002 Medline
  74. Westerholm-Ormio M, Vaarala O, Pihkala P, Ilonen J, Savilahti E: Immunological activity in the small intestinal mucosa of pediatric patients with type 1 diabetes Diabetes52 :2287 –2295,2003 Abstract/FREE Full Text
  75. Auricchio R, Paparo F, Maglio M, Franzese A, Lombardi F, Valerio G, Nardone G, Percopo S, Greco L, Troncone R: In vitro-deranged intestinal immune response to gliadin in type 1 diabetes. Diabetes53 :1680 –1683,2004 Abstract/FREE Full Text
  76. Virtanen SM, Knip M: Nutritional risk predictors of β cell autoimmunity and type 1 diabetes at a young age. Am J Clin Nutr78 :1053 –1067,2003 Abstract/FREE Full Text
  77. Gerstein HM: Cow’s milk exposure and type 1 diabetes mellitus: a critical overview of the clinical literature. Diabetes Care17 :13 –19,1994 Abstract/FREE Full Text
  78. Norris JM, Barriga K, Klingensmith G, Hoffman M, Eisenbarth GS, Erlich HA, Rewers M: Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA290 :1713 –1720,2003 Abstract/FREE Full Text
  79. Ziegler A-G, Schmid S, Huber D, Hummel M, Bonifacio E: Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. JAMA290 :1721 –1728,2003 Abstract/FREE Full Text
  80. Åkerblom HK, Virtanen S, Ilonen J, Savilahti E, Vaarala O, Reunanen A, Teramo K, Hämäläinen A-M, Paronen J, Riikjärv M-A, Ormisson A, Ludvigsson J, Dosch H-M, Hakulinen T, Knip M, the National TRIGR Study Groups: Dietary manipulation of beta-cell autoimmunity in infants at increased risk for type I diabetes: a pilot study. Diabetologia48 :829 –837,2005 CrossRefMedline
  81. Hyppönen E, Kenward MG, Virtanen SM, Piitulainen A, Virta-Autio P, Knip M, Åkerblom HK, the Childhood Diabetes in Finland Study Group: Infant feeding, early weight gain and risk of type 1 diabetes. Diabetes Care22 :1961 –1965,1999 Abstract/FREE Full Text
  82. Hyppönen E, Virtanen SM, Kenward MG, Knip M, Åkerblom HK, the Childhood Diabetes in Finland Study Group: Obesity, increased linear growth and risk of type 1 diabetes mellitus in children. Diabetes Care23 :1755 –1760,2000 Abstract/FREE Full Text
  83. Wilkin TJ: The accelerator hypothesis: weight gain as the missing link between type 1 and type 2 diabetes. Diabetologia44 :914 –922,2001 CrossRefMedline
  84. Pundziute-Lycka A, Dahlquist G, Nyström L, Arnqvist H, Bjork E, Blohme G, Bolinder J, Eriksson JW, Sundkvist G, Östman J, Swedish Childhood Diabetes Study Group: The incidence of type 1 diabetes has not increased but shifted to younger age at diagnosis in the 0–34 years group in Sweden 1983–98. Diabetologia45 :783 –991,2002 CrossRefMedline
  85. Strachan DP: Hay fever, hygiene and household size. Br Med J299 :1259 –1260,1989
  86. Bach JF: The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med347 :911 –920,2002 CrossRefMedline
  87. EURODIAB ACE Study Group and The EURODIAB ACE Substudy 2 Study Group: Familial risk of type I diabetes in European children. Diabetologia41 :1151 –1156,1998 CrossRefMedline
  88. Kostraba JN, Cruickshanks KJ, Lawlerheavner J, Jobim LF, Rewers MJ, Gay EC, Chase HP, Klingensmith G, Hamman RF: Early exposure to cow’s milk and solid foods in infancy, genetic predisposition, and risk of IDDM. Diabetes42 :288 –295,1993 Medline
  89. Pérez-Bravo F, Carrasco E, Gutierrez-Lopez MD, Martinez MT, Lopez G, de los Rios MG: Genetic predisposition and environmental factors leading to the development of insulin-dependent diabetes mellitus in Chilean children. J Mol Med74 :105 –109,1996 Medline
  90. Sadeharju K, Knip M, Hiltunen P, Åkerblom HK, Hyöty H, the Childhood Diabetes in Finland Study Group: The HLA-DR phenotype modulates the humoral immune response to enterovirus antigens. Diabetologia46 :1100 –1105,2003 CrossRefMedline
  91. Vaarala O, Klemetti P, Juhela S, Simell O, Hyöty H, Ilonen J: Effect of coincident entreovirus infection and cow’s milk exposure on immunization to insulin in early infancy. Diabetologia45 :531 –534,2002 CrossRefMedline
  92. Bingley PJ, Christie MR, Bonifacio E, Bonfanti R, Shattock M, Fonte MT, Bottazzo GF, Gale EAM: Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes43 :1304 –1310,1994 Medline
  93. Kulmala P, Petersen JS, Vähäsalo P, Karjalainen J, Löppönen T, Dyrberg T, Åkerblom HK, Knip M, the Childhood Diabetes in Finland Study Group: Prediction of insulin-dependent diabetes mellitus in siblings of diabetic children: a population-based study J Clin Invest101 :327 –336,1998 Medline